

Summary of CofixRX Testing

Utah State University Institute of Antiviral Research Report



Dr. Ravi Hedni 2021

Medical Director Clarkston Surgical Center

CONCLUSIONS: CofixRX Nasal Spray is 99.9% effective against SARS-CoV-2. It was 100% effective against Influenza B and RSV, and 94% effective against HRV-14. The combination of ingredients in CofixRX is highly virucidal against all four of the viruses tested in this laboratory analysis.

Test Restated/Interpreted by:

Charlie Fehl, Ph.D.

Medicinal Chemistry

Wayne State University 2022

CONCLUSIONS:

CofixRX Nasal Spray is >99.5% effective against SARS-CoV-2 variants of concern in this laboratory analysis. These new results add to previous test data that revealed CofixRX is also 100% effective against the viruses Influenza B (“flu”) and RSV (“respiratory syncytial virus”) and 94% effective against HRV-14 (“human rhinovirus B14”). The combination of ingredients, including povidone-iodine, in CofixRX is therefore highly virucidal against four distinct viruses tested, including two major variants of concern for SARS-CoV-2: delta and omicron.